AstraZeneca-Merck Lynparza gets EMA's positive recommendation
Drugmakers AstraZeneca Plc and Merck & Co Inc said on Monday their blockbluster cancer drug, Lynparza, has received positive recommendation from the European Medicines Agency (EMA) as a maintenance treatment for a form of pancreatic cancer. from Reuters: Health News https://ift.tt/2XmwWYg https://ift.tt/xePdMM